Published online before print April 24, 2003, doi: 10.1161/01.RES.0000073585.50092.14
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 4, 2002
Revised on April 7, 2003
Accepted on April 14, 2003
Peroxisome Proliferator-Activated Receptor Gamma (PPAR
) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth
Shingo Ameshima ;
From the Pulmonary Hypertension Center (S.A., N.F.V., R.W.V., S.J.G., M.W.G., N.F.V.), Division of Renal Medicine (R.A.N.), Cancer Center (R.A.N., M.W.G.), and Department of Pathology (C.D.C.), University of Colorado Health Sciences Center, Denver, Colo; National Jewish Research Center (R.W.V., S.J.G.), Denver, Colo; Pulmonary Division (H.G.), Universitätsklinik Magdeburg, Germany.
* To whom correspondence should be addressed. E-mail: Norbert.Voelkel{at}uchsc.edu.
PPAR
is a member of a family of nuclear receptors/ligand-dependent transcription factors, which bind to hormone response elements on target gene promoters. An antiproliferative and proapoptotic action profile of PPAR has been described and PPAR may function as a tumor suppressor gene, but little is known about the role of PPAR in vascular remodeling. One group of human diseases that shows impressive vascular remodeling exclusively in the lungs is the group of severe pulmonary hypertensive disorders, which is characterized by complex, endothelial cell-proliferative lesions of lung precapillary arterioles composed of clusters of phenotypically altered endothelial cells that occlude the vessel lumen and contribute to the elevation of the pulmonary arterial pressure and reduce local lung tissue blood flow. In the present study, we report the ubiquitous PPAR expression in normal lungs, and in contrast, a reduced lung tissue PPAR gene and protein expression in the lungs from patients with severe PH and loss of PPAR expression in their complex vascular lesions. We show that fluid shear stress reduces PPAR expression in ECV304 endothelial cells, that ECV304 cells that stably express dominant-negative PPAR (DN-PPAR ECV304) form sprouts when placed in matrigel and that DN-PPAR ECV304 cells, after tail vein injection in nude mice, form lumen-obliterating lung vascular lesions. We conclude that fluid shear stress decreases the expression of PPAR in endothelial cells and that loss of PPAR expression characterizes an abnormal, proliferating, apoptosis-resistant endothelial cell phenotype.
Key words: severe pulmonary hypertension • peroxisome proliferator-activated receptor
•
endothelial cell growth •
apoptosis •
shear stress
This article has been cited by other articles:
 |
|
 |
|
  L. Chang, L. Villacorta, J. Zhang, M. T. Garcia-Barrio, K. Yang, M. Hamblin, S. E. Whitesall, L. G. D'Alecy, and Y. E. Chen Vascular Smooth Muscle Cell-Selective Peroxisome Proliferator-Activated Receptor-{gamma} Deletion Leads to Hypotension Circulation, April 28, 2009; 119(16): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Rai, C. D. Cool, J. A. C. King, T. Stevens, N. Burns, R. A. Winn, M. Kasper, and N. F. Voelkel The Cancer Paradigm of Severe Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 558 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lawrie, E. Waterman, M. Southwood, D. Evans, J. Suntharalingam, S. Francis, D. Crossman, P. Croucher, N. Morrell, and C. Newman Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension Am. J. Pathol., January 1, 2008; 172(1): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Masri, W. Xu, S. A. A. Comhair, K. Asosingh, M. Koo, A. Vasanji, J. Drazba, B. Anand-Apte, and S. C. Erzurum Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L548 - L554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al. Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats Hypertension, September 1, 2007; 50(3): 531 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hansmann, R. A. Wagner, S. Schellong, V. A. de Jesus Perez, T. Urashima, L. Wang, A. Y. Sheikh, R. S. Suen, D. J. Stewart, and M. Rabinovitch Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator-Activated Receptor-{gamma} Activation Circulation, March 13, 2007; 115(10): 1275 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Voelkel, I. S. Douglas, and M. Nicolls Angiogenesis in Chronic Lung Disease Chest, March 1, 2007; 131(3): 874 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper, and N. F. Voelkel Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L668 - L676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. D. Achcar, Y. Demura, P. R. Rai, L. Taraseviciene-Stewart, M. Kasper, N. F. Voelkel, and C. D. Cool Loss of Caveolin and Heme Oxygenase Expression in Severe Pulmonary Hypertension Chest, March 1, 2006; 129(3): 696 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Cool, S. D. Groshong, J. Oakey, and N. F. Voelkel Pulmonary Hypertension: Cellular and Molecular Mechanisms Chest, December 1, 2005; 128(6_suppl): 565S - 571S. [Full Text] [PDF]
|
|
|
|
|
|
M. Bonay, C. Bancal, D. de Zuttere, F. Arnoult, G. Saumon, and F. Camus Normal Pulmonary Capillary Blood Volume in Patients With Chronic Infiltrative Lung Disease and High Pulmonary Artery Pressure Chest, November 1, 2004; 126(5): 1460 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, R. Shu, G. Filippatos, and B. D. Uhal Apoptosis in lung injury and remodeling J Appl Physiol, October 1, 2004; 97(4): 1535 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Akaike, W. Che, N.-L. Marmarosh, S. Ohta, M. Osawa, B. Ding, B. C. Berk, C. Yan, and J.-i. Abe The Hinge-Helix 1 Region of Peroxisome Proliferator-Activated Receptor {gamma}1 (PPAR{gamma}1) Mediates Interaction with Extracellular Signal-Regulated Kinase 5 and PPAR{gamma}1 Transcriptional Activation: Involvement in Flow-Induced PPAR{gamma} Activation in Endothelial Cells Mol. Cell. Biol., October 1, 2004; 24(19): 8691 - 8704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lin, X. Zhu, F. L. Mclntee, H. Xiao, J. Zhang, M. Fu, and Y. E. Chen Interferon Regulatory Factor-1 Mediates PPAR{gamma}-Induced Apoptosis in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 257 - 263. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. A. Culver, B. P. Barna, B. Raychaudhuri, T. L. Bonfield, S. Abraham, A. Malur, C. F. Farver, M. S. Kavuru, and M. J. Thomassen Peroxisome Proliferator-Activated Receptor {gamma} Activity Is Deficient in Alveolar Macrophages in Pulmonary Sarcoidosis Am. J. Respir. Cell Mol. Biol., January 1, 2004; 30(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tao, H.-R. Liu, E. Gao, Z.-P. Teng, B. L. Lopez, T. A. Christopher, X.-L. Ma, I. Batinic-Haberle, R. N. Willette, E. H. Ohlstein, et al. Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist in Hypercholesterolemia Circulation, December 2, 2003; 108(22): 2805 - 2811. [Abstract] [Full Text] [PDF]
|
|